Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2011. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share transaction event.
Material Changes
Following a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan, an increase in the notional allocation of Ordinary share ADRs occurred on February 4, 2011. The transaction price was $38.01 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: February 4, 2011.
- Transaction Price: $38.01 per ADR.
- Notional ADR Allocations Increased for: Dr K Belmonte (4), Mr W C Louv (9), Dr M M Slaoui (19), and Dr D Pulman (13).
- The transaction relates to the US Retirement Savings Plan and does not reflect direct cash purchases by the individuals.